JARID2 binding sites are most significantly enriched in the promoters of the dysregulated genes in GBM but in the cancer cells, specifically, there is also enrichment of the catalytic subunit of PRC2: Enhancer of zeste homolog 2 (EZH2; Figs. 3A). Here, EZH2 is linked to cancer.